6 Additional Pending Patent Applications Submitted for evo Smart Shippers, Liquid Nitrogen Dry Vapor
Shippers and Cold Chain SaaS Application
PR Newswire
ALBUQUERQUE, N.M., July 31, 2018
ALBUQUERQUE, N.M., July 31, 2018 /PRNewswire/ -- SAVSU Technologies , the leading developer of smart, precision biologic shipping containers and cloud-based cold chain management SaaS solutions, today announced that the
USPTO has issued a notice of allowance of patent number 10,018,614 B2, titled "Biologic Stability, Delivery Logistics and
Administration of Time and/or Temperature Sensitive Biologic Based Materials". The inventors are Bruce
McCormick, President of SAVSU Technologies, and Mike Rice, CEO of BioLife Solutions (NASDAQ:BLFS).
SAVSU has been granted 3 patents and has 6 other pending patent applications related to novel innovations incorporated into
current, or to be incorporated into future, precision thermal shipping containers under the evo brand, including models that
precisely maintain biologic payload temperature stability across the entire shipping continuum including -196°C using liquid
nitrogen dry vapor shippers, -80°C using dry ice, and 2° - 8°C and controlled room temperature (CRT) using conditioned phase
change insulating materials. These patent applications also include claims related to the evo.is Cold Chain Software as a Service
(SaaS) live cell visibility platform.
Bruce McCormick, commented, "This patent grant further validates our mission to offer truly
innovative biopreservation tools for regenerative medicine, with a focused and intentional goal to improve cold chain logistics
of cell and gene therapies. We believe the advanced and innovative evo hardware and software technologies will have
tremendous impact on the preservation, delivery, and quality management of these precious, time and temperature sensitive
biologic medicines."
About SAVSU
SAVSU is a leading designer and manufacturer of innovative high-performance cloud-connected passive storage and transport
containers for temperature sensitive biologics and pharmaceuticals. Our mission is to improve global health by greatly reducing
the waste and risks associated with the improper freezing and overheating of thermal-sensitive medicines and biologics. SAVSU has
developed proprietary state-of-the-art technology to ultimately lower costs and improve delivery of these most essential
materials. For more information please visit www.savsu.com .
View original content with multimedia:http://www.prnewswire.com/news-releases/savsu-technologies-awarded-new-patent-for-cold-chain-technologies-used-in-cell-and-gene-therapies-300688947.html
SOURCE SAVSU Technologies